Introduction Iron deficiency (ID) is a common finding in IBD. Previous studies have linked ID and thrombocytosis, which itself is a general risk factor for thromboembolic events. In the ThromboVIT trial (Inflamm Bowel Dis. 2013) IBD-associated thrombocytosis was responsive to iron replacement therapy.
Here, we tested the effect of iron replacement therapy on platelet activity.
Methods IBD patients with ID (ferritin < 100 μg/L or transferrin saturation < 16%) and remission/mild disease activity were included. Patients were randomized 1: 1 into treatment with ferric-carboxymaltose 1000 mg or placebo.
The primary endpoint was platelet aggregation (ADP-induced area under the curve; AUC) after 4 weeks; secondary endpoints included changes in p-selectin and sCD 40L, platelet counts, hemoglobin, iron parameters and inflammatory parameters.
Results Forty patients were randomized, 19 patients in each group were included in the per-protocol analysis. The ADP-induced platelet aggregation decreased in the iron but not in the placebo group, without reaching statistical significance (table 1). A similar trend was observed for sCD 40L. Platelet counts decreased in the iron but no placebo group. Hemoglobin and iron parameters increased as expected while inflammatory parameters did not change (table 2) . Subgroup analysis according to platelet counts (normal ≤ 350 G/L versus thrombocytosis > 350 G/L) revealed that patients with thrombocytosis displayed a statistical significant higher platelet aggregation (table 1) .
Conclusion
In this IBD cohort with mild ID and mostly clinical remission, platelet activity decreased upon iron replacement specifically in patients with thrombocytosis. Thus, ID increases both platelet activity and platelet counts and may contribute to an increase in thrombosis.
Tab. 1 Platelet parameters. Background IFIH1 (Interferon induced with helicase C domain 1) is an intracellular pattern recognition receptor which has been identified as a susceptibility locus for Ulcerative Colitis and Crohn's disease. IFIH1 has been described to recognize dsRNA, which results in induction of type I interferon. Interestingly, an interaction of IFIH1 with autophagy-associated proteins has been suggested. Thus we hypothesize that IFIH1 may join the ranks of NOD 2, which has also been implicated in the recognition of intracellular pathogens and autophagy. This study aims to identify a functional relation between IFIH1
and autophagy and its part in the pathogenesis of IBD.
Methods Autophagy was induced via nutrient deprivation, Rapamycin or Salmonella typhimurium in ΔIfih1-silenced cell lines and also in peritoneal macrophages from WT and IFIH1 -/-mice. In an in-vivo approach WT and IFIH1
-/-mice were challenged with Salmonella typhimurium.
Results IFIH1 deficiency interferes indeed functionally with autophagic activity. We observed a cell-type specific effect, which coincides with a differential immunohistochemical distribution of IFIH1 and its related protein RIG-I, with IFIH1 being predominantly expressed in intestinal epithelial cells (IECs) . Accordingly, we found low levels of autophagy in the epithelial scrapings of IFIH1 -/-compared to wild-type animals after challenge with Salmonella typhimurium. Similar results were observed in ΔIfih1 colonic epithelial Caco-2 cells, which additionally show an impaired ability to cope with these bacteria. In contrast, peritoneal macrophages and full-thickness intestinal samples of IFIH1 -/-mice showed significantly higher autophagic activity in response to Salmonella typhimurium than their wild-type controls.
Conclusion IFIH1-deficiency shows divergent effects on autophagy in different cell-types. Notably, in IECs, where IFIH1 is highly expressed normally, it caused a significant reduction of autophagic activity which may explain their impaired ability to cope with intracellular Salmonella typhimurium in vitro as well as the more severe infection in-vivo.
A07 Diagnostic delay in patients with inflammatory bowel disease -a study of the Austrian IBD study group (ATISG) Background Diagnostic delay seems to be common in inflammatory bowel disease (IBD), especially in Crohn's disease (CD). We sought to investigate the diagnostic delay in Austrian IBD patients and to identify associated risk factors as well as the impact of delayed diagnosis on the risk of intestinal surgery in
CD.
Methods In a multicentre cohort study adult patients with IBD (CD, ulcerative colitis UC, inflammatory bowel disease unclassified IBDU) attending 18 Austrian outpatient clinics were recruited between May 2014 and July 2015 to complete a multi-item questionnaire, which recorded medical and socioeconomic characteristics. Study outcome was the diagnostic delay defined as the time period between symptom onset to diagnosis of IBD. A multivariable proportional hazard regressions model based on interval censored latency times was calculated.
Results 1217 patients (CD 779, UC 400, IBD 21, missing 17; females 615) with a median age of 40 years (interquartile range (IQR) 31 -52 years) and a median disease duration of 10 years (IQR 4 -18 years) were analysed. The median diagnostic delay was 0.53 years (IQR 0.20 -1.92 years) in CD and 0.28 years (IQR 0.11 -0.86 years) in UC, respectively (p < 0.001). In the multivariable regression analysis patients with CD had a significantly longer diagnostic delay than patients with UC (HR 1.56; 95 % CI 1.34 -1.82; p < 0.0001) and a quadratic effect of age leading to higher risk of delayed diagnosis in older patients (p < 0.0001) was found. Diagnostic delay did not differ significantly between patients with intestinal CD-related surgery (53 % of all CD patients) and those without surgery. However, in the Kaplan-Meier curve for the probability of being diagnosed after symptom onset a trend of a difference between both groups was seen after 10 months (p = 0.13).
Discussion Diagnostic delay was longer in CD than in UC patients and was associated with older age at diagnosis. Background Due to demographic trends, there is a growing elderly population in western countries. As incidence of pancreaticobiliary diseases also increases with age the demand of endoscopic retrograde cholangiopancreatography (ERCP) in geriatric patients is growing. On the other hand, elderly patients have a higher frequency of comorbidities and as ERCP carries a substantial peri-and postprocedural morbidity, thus might have a higher risk of developing complications, especially in patients with advanced age of more than ninety years. We therefore aimed to investigate outcome of patients aged 90 years and older, which underwent an ERCP in our institution. (59 %, n = 78) and cholestasis (18%, n = 24). Further indications included cholangitis, pancreatitis as well as a biliary-leaks and previous stents. Midazolam and propofol was used for sedation in 98,5% of patients. Periprocedural complications occurred in 6% (n = 8). We noticed 5,3 % (n = 7) postinterventional complications with 5 pancreatitis (3.79%), one gallstone-ileus and one aspirations-pneumonia. Two patients died during follow-up.
Methods

Discussion
The numbers of ERCP's in geriatric patients aged more than ninety years are rising in our institution. The procedure seems to be safe with an acceptable complication-rate in this high-risk patient group, although an experienced team seems to be advisable. Background Bleeding stents may be superior to balloon tamponade for refractory esophageal variceal bleeding (EVB), however, data on safety and efficacy after the use of SX-ELLA "Danis-Stents" are limited.
A11 Endoskopische
Methods Retrospective multicenter study including cirrhotic patients receiving Danis-Stents for massive/refractory EVB at 4 tertiary care centers in Vienna. Bleeding control (5days), bleeding-related mortality (6weeks) and overall mortality were assessed.
Results Among 35 patients, 13 patients had an unsuccessful band ligation prior to Danis-Stent placement. Danis-Stent controlled EVB in 80% (28 /35) of patients. In the remaining n = 7 patients, n = 4 died of uncontrolled EVB, n = 2 experienced bleeding-related mortality, and only 1 patient achieved a successful long-term bleeding control. In total, early-rebleeding within 6 weeks occurred in 14.3% (including n = 1 while Danis-Stent was still in place and n = 5 after Danis-Stent was removed). Moreover, among n = 14 patients without early rebleeding within 6 weeks, only n = 3 (21.4%) showed rebleeding later during follow-up. Only n = 11 (31.4 %) patients did not experience any rebleeding after Danis-Stent removal, while n = 8 patients died with the Danis-Stent in situ. Notably, no "early-TIPS" was performed in this study, but 4 (11.4 %) received an elective TIPS during follow-up. N = 6 patients (17.1 %) died due to uncontrolled bleeding (≤ 5days) and n = 10 died within 6 weeks (bleeding- , Dienhart C Aim This prospective non-interventional study compared the bowel preparation quality according to the Harefield Scale as well as performance quality measures of colonoscopy within screening colonoscopies performed within the "Qualitätszeritfikat Darmkrebsvorsorge" using the following purgatives:
Results 4124 colonoscopies performed by 20 endoscopists were included in this study, 50.4% of patients were women. Overall cecal intubation rate was 98.5 %, detection rate for polyps was 44.1%, adenomas 25.1 %, and advanced adenomas 8.7 %. In 96.1 % of colonoscopies bowel preparation was successful (Harefield Scale A or B), in 3.9% unsuccessful (Harefield Scale C or D). Success rates did not differ between male and female individuals (95.6 % vs. 96.6 %, respectively, p = 0.088). All purgatives met the required quality standards of > 90% success rate and adenoma detection rate of ≥ 20%. However, there was a significant difference in success rate between the purgatives used (p < 0.001). Conclusion Although success rate differed between the purgative used, in the present study cohort bowel preparations quality with every investigated purgative met the required quality standards of > 90 % success rate and adenoma detection rate ≥ 20%. Objective Iron deficiency (ID) is a common finding especially in young woman and impacts physical and cognitive function as well as quality of life. Current guidelines recommend only the evaluation of coeliac disease in premenopausal woman. We hypothesize that autoimmune gastritis (AIG) is a common finding in ID.
A24 ERCP in Österreich
Design We did a retrospective analysis of patients who attended an outpatient clinic specialized for ID. Patients with ferritin < 50 μg/L or transferrin saturation < 15% were included. Laboratory work-up included endomysial antibody and parietal cell antibody (PCA). Endoscopy was recommended if antibody were positive. PH of gastric juice was measured during gastroscopy.
Histologic slides were evaluated by a routine pathologist and an expert pathologist.
Results We included 409 patients with ID, about half of patients were anemic.
Patients were predominately female with a median age of 39. Elevated levels of PCA were found in 72 (18.5 %) patients. Gastroscopy was performed in 28 patients, in 9 (32.1 %) the diagnosis of AIG was confirmed primarily, all had PCA levels > 100U/mL. Re-evaluation of an expert pathologist increased the number of AIG to 13 and three additional patients diagnosed as early/questionable AIG. A sensitivity of 94 % and a specificity of 98% was estimated for a PCA cut-off of 100U/mL. Achlorhydria was found in 8 patients, all with AIG.
Coeliac disease was found in four (1 %) patients.
Conclusion AIG is a common finding in patients with ID. PCA are a highly sensitive and specific tool for diagnosis of AIG. Histological scores are needed especially in earlier stages. We conclude that PCA should be included in the non-invasive work up of iron deficiency as undiagnosed AIG may lead to serious complication including pernicious anemia, neuroendocrine tumors, and gastric adenocarcinoma. Separate logistic regression models were performed with PALM, FM and all potential biomarkers of TRP metabolism (model 1) and additively with the CAAs (model 2) to assess the effect on depression, defined as a BDI II score
Results In all logistic regression models, FM was significantly associated with signs of depression (p = 0.001), whereas no relationship was shown for PALM.
In the logistic regression model 1 the TRP index was inversely associated with signs of depression (p = 0.006), whereas the TRP index and also the CAAs were no predictors of depressive signs in the logistic regression model 2.
Conclusion In all logistic regression models calculated here FMA was shown to be associated with a BDI II score > 8, whereas primary-adult LMA demonstrated no effect on signs of depression.
A28 EDTA compounds, used for food stabilizing agents, aggravate inflammation and drive tumorigenesis in a mouse model of colitis-associated carcinogenesis Western lifestyle is associated with increasing prevalence of IBD, processed food being a likely cause. We have shown that ferric EDTA, used for iron fortification, but not other iron agents aggravate gut inflammation and colitis-associated cancer (CAC) in mice. We extend our observations to other EDTA compounds, which are used in the food industry as stabilizing agents.
We compared Fe-EDTA, Ca-EDTA and Na-EDTA at 1161 mg EDTA/kg chow (no observed adverse effects level) to a control diet. Fifteen C 57BL/ 6 mice per group were fed these diets and received AOM (azoxymethane) intraperitoneally. Two DSS (dextran sodium sulphate) cycles followed. Colitis activity (weight, stool consistency and presence of blood in the stools by Guaiac test) was monitored throughout the experiment. Upon sacrifice, intestines were collected, and the presence of inflammation and tumors was examined microscopically.
All EDTA compounds led to increased colitis activity. Results Thirty-one patients (65%) showed psychological distress, twenty-two (31 %) anxiety, and ten depression (21%). Microbial beta diversity was signifi- Conclusion Psychological variables had a high discriminative value for gut microbial composition, underscoring the role of brain-gut-microbiota interaction in IBS.
Supported by Austrian Society of Gastroenterology and Hepatology (ÖGGH) and funds of the Oesterreichische Nationalbank, Fund project number: 16506. Background and aims SSC-CIP is a progressive, cholestatic liver disease with enigmatic pathophysiology. Ischemic injury of the biliary system, bile cast formation and recurrent biliary infections are discussed as major factors. Since it occurs only in small proportion of patients surviving a critical illness, patient factors seem to be important in the pathogenesis. The aim of the study was to characterize gut microbiome composition and gut permeability in SSC-CIP patients in comparison to healthy controls.
Methods Serum and stool from 18 patients (mean age 59 ± 13, 5 women, 39% cirrhosis) with SSC-CIP from two centers in Austria and Germany and from 21 healthy controls were collected. Patients were included when they developed sclerosing cholangitis diagnosed by ERCP or MRCP after a critical illness. Gut permeability was assessed by diamino-oxidase (DAO, serum), zonulin and calprotectin (stool) using ELISA. sCD 14 and lipopolysaccharide binding protein (LBP) as markers for endotoxemia were measured by ELISA in serum. 16S rDNA was isolated from stool, sequenced using Illumina technique and analysed using QIIME.
Results SSC-CIP patients had a significantly reduced alpha-diversity (chao1 p < 0.001). Significant differences in Beta Diversity could be shown 
Conclusions
The novel ElastPQ ® point-shear wave method represents a rapid and sensitive method for non-invasive diagnosis of significant liver fibrosis (L-ElastPQ > 6.1 kPa) and cirrhosis (L-ElastPQ > 12.1 kPa). Since spleen stiffness correlates with the degree of portal hypertension, a diagnostic algorithm using a Spleen-ElastPQ cut-off at 20 kPa together with a platelet cut-off at 150 G/L is accurate for non-invasive diagnosis/exclusion of CSPH. Results Among n = 221 patients with cirrhosis and refractory ascites, n = 140 received ePTFE-TIPS and were compared to n = 71 undergoing repetitive LVP +A. After ePTFE-TIPS, ascites was controlled without need for paracentesis in n = 76 (54%; n = 7 without and n = 69 with diuretics). Background & Aim HCV therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We showed SIGFIB or even ADVFIB, respectively, and 78 %(18/ 23) finally received interferon-free treatment.
A39 ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis
Overall, only 20%(42 /210) of HIV/HCV received interferon-free treatment.
Conclusion FIB-4 was not useful for ruling out ADVFIB in our cohort of HIV/ HCV. Treatment was initiated only in a small proportion of HIV/HCV during the first two years of IFN-free treatment availability, although the observed proportion of patients with SIGFIB (assessed by TE) was considerably higher (58 %). Thus, it requires the ongoing combined efforts of both HIV and HCV specialists to increase treatment uptake rates in this special population.
A41 Vascular function in hepatitis C patients -a cross sectional study 
A43 Targeting the Role of IL-37 in ALD
Authors Grabherr F 1 , Grander C 1 , Wieser V or vehicle every other day. On day 20 mice were sacrificed, tissue samples collected and properly stored.
Results MCD-diet feeding led to significantly enhanced liver injury, indicated by increased ALT levels and expression of pro-inflammatory cytokines like Tnfa, Mip-1 and Cd-68. Akkermansia muciniphila administration strongly tended to reduce Mip-1 (p = 0,142) and Tnf-a (p = 0,307), whereas ALT levels remained unaltered. Moreover, MCD-diet feeding increased hepatic triglyceride accumulation and altered expression of Cpt-1. However, Akkermansia muciniphila treated mice exhibited only some minor effects on lipid-metabolism. Goals In this analysis, we investigated PROs as well as effectiveness in realworld for the treatment regimen of OBV/PTV/r ± DSV ± RBV.
Conclusion
Methods GT1 and GT4-infected patients, participating in the multi-center, non-interventional cohort study REAL (NCT02582658) in Austria receiving OBV/PTV/r ± DSV ± RBV, were included in this analysis. Efficacy was assessed by SVR12. Health-related quality of life (HRQoL) and work productivity were assessed by standardized questionnaires (EQ-5D-5L; WPAI Hep C V2.0; PAM-13). Conclusions This study demonstrated for the first time that the treatment with OBV/PTV/r ± DSV ± RBV did not negatively impact HRQoL and total activity of patients in a real-world setting in Austria. SVR12 rate was similar to those seen in previous clinical trials. Background Little is known about the effects of sustained virological response (SVR) on liver fibrosis. SVR due to antiviral therapy might be associated with decrease of liver fibrosis. Therefore we investigated the effects of DAA based HCV therapy on fibrosis and cirrhosis measured by TE.
Methods 181 patients with baseline evaluation including TE and laboratory examination who achieved SVR were followed up at least one year after end of treatment (EOT). TE results were classified as very reliable (IQR/M ≤ 10 %), reliable (IQR/M ≤ 30% or ≥ 30 % and < 7,5kPa) and not reliable (IQR/ M > 30%). Patients were divided into two groups (cirrhosis vs. non cirrhosis)
according to baseline TE results (F4 > 13kPa). Only patients with correct TE results were included in statistical analysis. 12 months after EOT TE and laboratory evaluation were repeated to assess regression of fibrosis. Cirrhotic patients with liver related events during follow-up period had a median baseline TE of 28 kPa (IQR 14 -62).
Results Median TE prior to DAA therapy was 12 kPa (IQR 9 -21) and 8 kPa (IQR 5 -12) one year after therapy in the total patient population (p < 0.0001).
Patients without cirrhosis had median TE values of 9 kPa (IQR 6 -11) before and 7 kPa (IQR 7 -8) after therapy (p < 0.0001); cirrhotic patients had median TE values of 21 kPa (IQR 14 -29) and 12 kPa (IQR 9 -21) respectively (p < 0.0001). this is also true for alcohol and whether this regulatory mechanism is disrupted in alcohol addiction.
To investigate the effects of alcohol intake on FGF21 expression we enrolled 6
healthy volunteers who ingested a single binge of alcohol (2 g alcohol/kg bodyweight) in fasting state. The binge resulted in an increase of blood alcohol levels to 1.12 (± 0.14) ‰ one hour after intake. FGF 21 increased ten-fold from 399 (± 258)pg/ml at baseline to 3753 (± 1328)pg/ml within two hours after the binge. While blood alcohol levels decreased continuously with a rate of 0.11 (± 0.03) ‰/h, FGF21 levels remained elevated throughout the study period.
Alcohol consumption of 75 patients with cirrhosis of various aetiologies was assessed in interviews/questionnaires, and verified by urinary ethylglucuronid.
None of the patients had consumed alcohol immediately before inclusion (verified by urinary ethanol), 13 had elevated ethylglucuronid levels. We found that FGF21 in patients with ongoing alcohol consumption was 2.8-fold higher compared to abstinent patients (p = 0.003).
Our data show that alcohol intake results in a rapid increase in FGF21 levels in humans, possibly as a protective mechanism against intoxication, since FGF21 decreased alcohol intake in mice. The continuous alcohol intake in patients despite high FGF21 levels suggests a dysregulation of FGF21 and/or its receptors. Methods Five hundred and fifty one patients with advanced fibrosis (F3, n = 157) or cirrhosis (CPS-A: 319, CPS-B/C: 75) and sustained virologic response after interferon and ribavirin-free DAA therapy were studied with a median follow-up of 12.2 months (range3.0 -32.9). Only patients without hepatocellular carcinoma at baseline or liver transplantation were included.
A51 Protonenpumpenhemmer bei
Results During follow up 10 patients (1.8 %) died: the mortality rate was 0.06 % in F3, 1.6% in CPS-A and5.3 % in CPS-B/C patients. Thirteen patients Direct acting antivirals (DAA) have revolutionized hepatitis C therapy. We have previously shown that first generation protease inhibitors were associated with neutrophil dysfunction. We aimed to investigate neutrophil phagocytosis under DAA regimen with or without protease inhibitors.
A real life cohort of 85 patients (mean age 57 ± 11 years; 34 female) undergoing DAA therapy (66 % cirrhotics) was studied. Neutrophil phagocytosis was analysed at baseline, after 12 weeks of therapy (EOT) and after 12 weeks follow-up (FU12) by flow cytometry (Phagotest). Data were compared to 21 healthy controls (mean age 58 ± 7, 12 female).
Twelve patients received sofosbuvir/ribavirin, 14 sofosbuvir/daclatasvir, 19 sofosbuvir/simeprevir, 23 sofosbuvir/ledipasvir and 17 paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin. Overall SVR rate was 86% and 6 infections occurred. Baseline phagocytosis was significantly reduced compared to controls, but was similar in cirrhotic and non-cirrhotic patients.
Neither protease inhibitor containing therapy nor any other regimen impacted negatively on phagocytosis. The number of inactive neutrophils significantly decreased and phagocytosis significantly increased from baseline to FU12. The increase in phagocytosis was significantly more pronounced in patients who achieved SVR than in those who did not (p < 0.01). Neutrophil count was within normal range in all patients during the study. Patients achieving SVR showed higher neutrophil counts at baseline compared to non-achievers (3 vs.
2.5*10^9 /l, p < 0.05) and significant further increase during therapy (p < 0.001). Baseline phagocytosis was comparable with and without SVR.
Phagocytosis is impaired in chronic HCV, but improves during and after DAA therapy, even if SVR is not achieved. In contrast to therapies with first generation protease inhibitors, neither of the DAA regimens impacted negatively on neutrophil function. DAAs were not associated with severe infections.
These data underpin the importance of DAA therapy not only for liver health but also for innate immunity. (RAV) play a major role. The proportion of relapses and the specific RAV pattern might be of interest. Therefore we decided to present a "work up" of our patients who relapsed.
Methods Between 6 /2014 and 1 /2017 292 patients (median age 60 ± 27 SD; m 65,4 %) were treated for HCV and had a follow up of at least 12 weeks. In total 13 (4, 5%) experienced relapse during follow up. All of them were male.
In ten patients relapse was detected at follow-up week 4, in three patients
relapse occurred at follow-up 12. Four patients were retreated according EASL guidelines and and two out of them experienced cure. Six patients with relapse were tested for a specific resistance. All of them had different mutations in the NS 5A (Q/R30 (3x); Y93 H; L 31V), one patient had an additional NS 3 mutation (D 168V) and another one an additional nucleosidic NS 5B mutation (M414I) was detected in one.. Details will be displayed at the meeting.
At the time of the conference we will be able to present the cure rate of the patients' retreated according to EASL guidelines compared to those retreated after specific RAV testing.
Conclusion Relapse is a rare event in the DAA era. However the knowledge of RAVs might play an important role in the choice of second line treatment. The frequencies of the different RAVs might be of interest. For sure an Austrian or even better a European database would be of interest. SVR rates comparing those retreated with or without resistance testing will be presented at the meeting.
A56 Sofosbuvir/ledipasvir in combination with ribavirin shows high SVR12-rates in genotype-3 infected patients -experience from an austrian real world cohort Background and Aims Current EASL guidelines recommend treatment of genotype (GT) 3 infected patients with sofosbuvir in combination with either daclatasvir or velpatasvir. However, in many parts of Austria only cirrhotic patients have access to these treatment regimens and for non-cirrhotic patients only sofosbuvir/ledipasvir plus ribavirin is reimbursed by insurances.
Only small studies have been published concerning the efficacy of this regimen in GT3 patients. We report real world data of GT3 patients treated with sofosbuvir/ledipasvir in combination with ribavirin for 12 weeks.
Methods 55 GT 3 infected patients from three centers in Austria received a fixed dose combination of sofosbuvir/ledipasvir plus ribavirin 800 -1200 mg daily over a period of 12 weeks. Prior to therapy non invasive staging of liver fibrosis was performed using transient elastography. Baseline characteristics of patients were as follows: male/female: 38 /17; treatment naïve/experienced: 44/ 11; mean age ± SD: 46.1 ± 9.3 years). The proportion of patients with cirrhosis was 32.7 % (n = 18).
Results 48 patients had a sustained virologic response (SVR12), 3 patients relapsed and 4 were lost to follow-up. SVR12 rate in the ITT population was 87.3 %. In treatment naive and treatment experienced patients SVR rate was 90.9 % and 72.7 %, respectively. SVR12 rate was 83.8 % in precirrhotic patients and 94.4% in patients with compensated cirrhosis. In the modified ITT analysis excluding patients lost to follow-up SVR rate was 94.1 %; 100% in cirrhotic and 91.2 % in non-cirrhotic patients; in treatment naive patients SVR was 95.2%
and 88.9% in treatment experienced. There were no treatment discontinuations due to adverse events. RAS analysis was performed in relapsed patients;
none of the relapsed patients tested positive for NS 5A RASs.
Conclusions SOF/LDV/RBV can be considered for treatment of GT3 patients, if the combinations sofosbuvir/daclatasvir and sofosbuvir/velpatasvir are either not available or not reimbursed by insurances.
A57 Directly observed therapy with sofosbuvir/ ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy Background An important subgroup of people who inject drugs (PWID) receives opioid agonist therapy (OAT) under direct observation of a physician or nurse at a low-threshold drug treatment facility or pharmacy on a daily basis.
Most of these patients suffer from psychiatric comorbidities and are reluctant or unable to go to specialized hepatitis centers. Our hypothesis was that chronic hepatitis C in these difficult-to-treat patients could be optimally managed if modern, interferon-free regimens were applied together with OAT under direct observation of a physician or nurse at a low-threshold drug treatment facility.
Methods In this non-interventional study (ClinicalTrials.gov number, NCT02638233), 40 PWID with borderline compliance and previously un- Sustained virologic response (SVR12) was confirmed in all 40 patients (SVR12 rate: 100%).
Conclusion Directly observed therapy of chronic HCV GT1 infection with sofosbuvir/ledipasvir for 8 weeks at a low-threshold drug treatment facility is highly effective in treatment-naïve, precirrhotic patients with borderline compliance receiving OAT. By this concept chronic hepatitis C can be cured in a group of difficult-to-treat patients, who are unable to be treated at hepatologic centers. This study was supported by Gilead Sciences.
A58 Fulminantes Leberversagen unklarer Ätiologie
Autoren Nowak M Background Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies.
Objective To investigate the effect of RAS inhibitor ( Consecutive sequencing of both, the 5'UTR-core region as well as the NS 5B genome region was crucial to enable the correct diagnosis and treatment. Background Acute variceal bleeding (AVB) represents a severe complication of portal hypertension. Despite a decrease in mortality over the last decades, AVB-related mortality remains considerable. Recent data on the outcome and survival after AVB are limited.
Methods
We assessed bleeding control (5 days), early rebleeding rates and bleeding-related mortality (6 weeks) and overall mortality in cirrhotic patients with AVB admitted to the Medical University Vienna ( Conclusion We observed high bleeding-related mortality -which may be explained by the long study period and implementation of early TIPS only after 2010. MELD was the only independent prognostic factor for 6-week bleeding-related mortality. AVB while-on NSBBs had no influence on rebleeding or mortality. In addition to MELD and Child-Pugh stage, the presence of PVT was associated with rebleeding within the first year after AVB. In addition the presence of PVT was negatively associated with transplant-free survival. Homozygous alpha-1 antitrypsin (A1AT) deficiency (Pi*ZZ) is a known risk factor for the development of liver cirrhosis, but the risk conferred by heterozygosity for the Z allele (Pi*MZ) is controversial. Epidemiological studies in unselected cohorts suggests that heterozygous alpha-1 antitrypsin deficiency (A1ATD) is not associated with an increased risk for cirrhosis.
To determine the actual risk of liver cirrhosis, iron overload and hepatic decompensation conferred by heterozygosity for Pi*Z and to assess the burden of A1ATD in patients with cirrhosis, the common A1ATD risk alleles (Pi*S and Pi*Z) were genotyped in a cohort of 1516 patients and 248 liver donors.
In patients with cirrhosis the prevalence of heterozygosity for MZ is 3.5-fold higher than in liver donors (9.3% vs. 2.8 %, p =< 0.001). The prevalence of MZ heterozygosity in the latter group matched the expected frequency of the general Austrian population (2.9 %). This overrepresentation of A1AT-deficiency alleles was not observed for S-allele carriers. Although, the MZ genotype was more common among patients with cirrhosis, no increased risk of decompensation, HCC or liver transplantation was found. Median MELD-score was higher in the MZ genotype than in the MM group (14 vs. 12 points) but did not reach statistical significance. Across different genotypes, significant differences in serum iron parameters were observed with higher median ferritin and transferrin saturation in patients with MZ and ZZ genotypes. Analysis of patients with various underlying etiologies showed marked variability in the frequency of MZ heterozygosity, where the highest prevalence was found among patients with cryptogenic cirrhosis (12.9 %) followed by HCV (9.8. %) and alcoholic cirrhosis (7.3 %).
The high prevalence of heterozygosity for MZ among liver transplant recipients and patients with cirrhosis suggests that A1ATD is an important cofactor in the development of liver cirrhosis.
higher serum albumin levels at end of FU (+9 %/+3.6 g/L vs. -2 %/-0.65 g/L, p = 0.04). angiogenesis (CD 31, VEGFR2) and inflammation (TNFa) were determined by western blotting (normalized to GAPDH; expressed as x-fold of control). Moreover, the course of transaminases was assessed in 31 patients with heart failure (HFpEF) after initiation of RIO therapy.
Conclusions
Results BDL-W3 rats showed significantly increased CK19 area, phosphorylated (p)-moesin, myosin and VEGFR2, while inflammatory marker remained unchanged. In the stage of fibrosis, RIO inhibited ductular proliferation (CK19:
6.14 ± 1.85 vs. 3.58 ± 0.81 %; p = 0.005), decreased sinusoidal vasoconstriction (Hardy et al, 2013) . The aim of the present study was to evaluate these criteria in an independent cohort of patients with biopsy-proven ASH. Background Px-104 is an orally available, non-steroidal agonist of the farnesoid X receptor (FXR) as key regulator of bile acid, glucose and lipid homeostasis. This was the first clinical study with Px-104 in NAFLD patients.
Conclusion
Aims and Methods
We performed a proof of concept phase IIa study to evaluate efficacy, safety and tolerability of Px-104 in non-diabetic NAFLD patients. 21 NAFLD patients were enrolled diagnosed by liver biopsy or ultra- Results 12 patients were allocated to treatment. A significant decrease in ALT (22 %, p = 0.027; 1-tailed) and GGT (50 %, p = 0.019; 1-tailed) was observed after 4 weeks ( Results A 68-year old female patient with isolated hyperferritinemia and normal transferrin saturation chronic presented with coincident chronic hepatitis C virus (HCV) infection. T2* magnetic resonance imaging showed markedly splenic iron overload but only mild hepatic storage. Transient elastography of the liver by fibroscan and MRE showed no evidence of liver fibrosis. In vitro, the p.Arg178Gln mutant ferroportin localized to the plasma membrane, but iron export was reduced and correspondently intracellular ferritin concentration was augmented when compared to the normal ferroportin. Although hepcidin binding was similar in the normal and the R178Q mutant ferroportin, flow cytometry studies showed that the latter has lower responsiveness to hepcidin.
Conclusion
The results from our molecular and clinical studies support an existing pathogenic link between loss of ferroportin function and hepcidin ROC curve analysis showed that a transferrin concentration of 180 mg/dl is at the highest prognostic accuracy to predict 3-months and 1-year survival.
When patient subgroups with MELD ≥ 15 and < 15 were analyzed, transferrin remained significantly associated with transplant-free survival in the subgroup with a MELD score < 15.
Conclusion Our study shows that the association of transferrin with survival is independent of MELD score even at early stages of liver cirrhosis. This finding can improve the prognostic evaluation in patients with liver cirrhosis and suggests that interventions targeted at iron handling might improve outcome. Ziachehabi A e32, e33, e34, e36, e42, e46, e53 Zoller H e42, e45, e49, e52, e53 
A74 Therapie der malignen Gallengangsobstruktion
